Kingsview Wealth Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,350
Closed -$233K 884
2022
Q1
$233K Sell
1,350
-859
-39% -$145K 0.01% 777
2021
Q4
$561K Sell
2,209
-1,141
-34% -$334K 0.02% 544
2021
Q3
$1.29M Buy
3,350
+927
+38% +$342K 0.06% 310
2021
Q2
$570K Sell
2,423
-99
-4% -$17.7K 0.03% 525
2021
Q1
$334K Buy
+2,522
New +$365K 0.02% 606

Other funds holding MRNA

Kingsview Wealth Management's MRNA Position: Q2 2022 in Review

Kingsview Wealth Management sold out of Moderna (MRNA) in Q2 2022, closing a stake of 1,350 shares — an estimated $233K sold.

Kingsview Wealth Management first reported a position in MRNA in Q1 2021 and held it in 5 quarters. The position peaked at $1.29M in Q3 2021. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Kingsview Wealth Management reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
  • Kingsview Wealth Management sold 1,350 Moderna shares in Q2 2022, an estimated $233K.
  • Kingsview Wealth Management first reported a position in Moderna in Q1 2021 and held it in 5 quarters.
  • Kingsview Wealth Management's Moderna position peaked at $1.29M in Q3 2021.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Kingsview Wealth Management's 13F filing for Q2 2022, filed 16 Aug 2022.